Englander Institute for Precision Medicine
Credit: Dr. Helen Kuo

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.

...
News from the EIPM!

A type of brain cancer, called glioma, tends to progress toward greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

The findings showcase the power of modern laboratory technology for illuminating cancer development, and could inform future treatments and...

Credit: Dr. Jonathan Zippin

An NSAID-related compound called ampyrone appears to safely boost production of the pigment melanin in human skin, according to a preclinical study led by Weill Cornell Medicine and National Eye Institute investigators. The discovery could lead to the development of an ampyrone-derived treatment for hypopigmentation disorders.

Such disorders, which include severe genetic forms of oculocutaneous albinism (OCA)...